Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

Abstract

Dynogen Pharmaceuticals Inc, under license from Mitsubishi Pharma Corp, is developing pumosetrag (MKC-733, DDP-733), an orally available gastroprokinetic agent and locally acting 5-HT3 partial agonist, for the potential treatment of irritable bowel syndrome (IBS) with constipation and nocturnal gastroesophageal reflux disease (GERD). In September 2005, Dynogen commenced a phase II proof-of-concept trial of pumosetrag in IBS with constipation; positive results were reported in February 2007 and a phase IIb trial was to start in the fourth quarter of 2007. In September 2006, the company had initiated a phase Ib trial in nocturnal GERD.

• Authors: Stefano Evangelista
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 8 Issue 5 Pg. 416-22 (May 2007) ISSN: 1472-4472 [Print] England
• PMID: 17520871 (Publication Type: Journal Article, Review)

Chemical References

• Dopamine Agents
• Gastrointestinal Agents
• Pyridines
• Quinuclidines
• Receptors, Serotonin, 5-HT3
• Pumosetrag

Topics

• Animals
• Dopamine Agents (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Gastroesophageal Reflux (drug therapy, metabolism)
• Gastrointestinal Agents (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Humans
• Irritable Bowel Syndrome (drug therapy, metabolism)
• Pyridines (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Quinuclidines (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Receptors, Serotonin, 5-HT3 (drug effects, metabolism)
• Treatment Outcome